Trade Johnson & Johnson with LHFX

Johnson & Johnson is one of the largest healthcare companies in the world, with around $87 billion in annual revenue across two operating segments after the August 2023 spin-off of the consumer business. Innovative Medicine (formerly Pharmaceuticals) is around two thirds of revenue and houses the drug franchise: immunology (Stelara, Tremfya), oncology (Darzalex, Carvykti, Erleada), neuroscience (Spravato, Invega), and infectious disease and vaccines. MedTech (around one third of revenue) covers orthopaedics, surgery (DePuy Synthes), interventional solutions, and vision (Acuvue contact lenses). The consumer business (Tylenol, Listerine, Band-Aid, Neutrogena, Johnson's Baby) was spun off in 2023 as Kenvue, listed separately under the ticker KVUE. J&J retained no operational consumer exposure post-spin, simplifying the equity story into a pure pharma plus medical-device combination. The spin removed the talc-litigation overhang from the consumer side (those liabilities stayed with J&J subsidiaries) but the broader talc litigation remains an active legal matter. The near-term thesis centres on the Stelara loss of exclusivity (biosimilar entry started 2024 in Europe and 2025 in the US). Stelara peaked at around $10 billion in annual revenue and is one of the largest single-drug LOEs in pharma history. The MedTech segment is positioned to absorb growth pressure via robotic surgery (Monarch endoluminal platform, Ottava general surgery in development) and Abiomed (acquired 2022 for $16.6 billion). At LHFX you trade JNJ as a CFD on the Johnson & Johnson share price. You profit or lose based on price movement and can go long or short. You do not own the share, have no voting rights, and dividends are passed through as a dividend adjustment on the ex-date. Maximum leverage on US single-stock CFDs is 1:20. Spreads are raw with a $3 per side commission. J&J has raised its dividend for 62 consecutive years and is a Dividend Aristocrat. Current dividend is around $1.24 per share quarterly.

Open an LHFX account, complete verification, and fund it from $10. Search JNJ in MetaTrader 5 or LHFX Trade. US cash hours apply: 14:30 to 21:00 UTC, Monday to Friday. CFDs pay a daily swap on positions held overnight, and dividends are passed through as a dividend adjustment on the ex-date. JNJ is a low-volatility healthcare name. Average daily range is around 0.9 to 1.2%, comparable to consumer staples like KO and PG. Illustrative sizing at a $155 share price: a 20-share JNJ position is $3,100 of notional and requires $155 of margin at 1:20 leverage. A 5% adverse move costs $155. Round-trip commission on 20 shares is $6. JNJ reports earnings mid-January, mid-April, mid-July, and mid-October before the US market open. Implied moves on earnings have run 2 to 4%, modest by S&P 500 standards. The ex-dividend date is typically late February, late May, late August, and late November. Major medical conferences (ASCO in early June, ASH in December) are scheduled platforms for oncology data readouts on Carvykti, Talvey, Tecvayli, and the broader bispecific antibody pipeline. These dates produce news flow outside earnings. Talc litigation settlement headlines can hit at any time and produce 2 to 5% single-day moves. Set a stop loss before entry. For a $2,000 account risking $40 per trade at a $2 stop distance, position size is around 20 shares.